Document is current
Any future updates will be listed below
-
Authors
Neuhann, Julia M. https://orcid.org/0000-0003-4479-6322
Stemler, Jannik https://orcid.org/0000-0001-9152-2469
Carcas, Antonio https://orcid.org/0000-0003-1823-4174
Frías-Iniesta, Jesús https://orcid.org/0000-0001-9538-9677
Bethe, Ullrich https://orcid.org/0000-0001-9979-1671
Heringer, Sarah https://orcid.org/0000-0001-7680-0344
Tischmann, Lea https://orcid.org/0000-0003-0178-0670
Zarrouk, Marouan https://orcid.org/0000-0002-3259-6123
Cüppers, Arnd https://orcid.org/0000-0001-8971-9481
König, Franz https://orcid.org/0000-0002-6893-3304
Posch, Martin https://orcid.org/0000-0001-8499-8573
Cornely, Oliver A. https://orcid.org/0000-0001-9599-3137
-
Funding
Funding for this research was provided by:
H2020 European Research Council (101037867)
Universitätsklinikum Köln
- License Information
-
More Information
Article History
Received: 28 July 2022
Accepted: 26 September 2022
First Online: 8 October 2022
Declarations
:
: The study is approved by the corresponding ethics committees. Amendments were and will be implemented only after approval of the EC. All patients gave written informed consent before study participation.
: Not applicable.
: JN, no conflicts declared.JS has received research grants by the Ministry of Education and Research (BMBF) and Basilea Pharmaceuticals Inc.; has received speaker honoraria by Pfizer Inc. and Gilead; has been a consultant to Gilead, Produkt&Markt GmbH, Alvea Vax. and Micron Research and has received travel grants by German Society for Infectious Diseases (DGI) and Meta-Alexander Foundation.AnC, no conflicts declared.JF has received research grants by the Instituto de Salud Carlos III, Ministry of Science. Spain. Has received grants or research contracts from Laboratorios Faes, Normon, Pfizer, Italfarmaco, GSK, Prestige, has been a consultant or has received speaker honoraria from Faes, Normon, Cinfa, Mundipharma, Abbott, Novartis and docency colaborations from Abbvie.UB, no conflicts declared.SH, no conflicts declared.LT; no conflicts declared.MZ has received honoraria for lecturing courses by Pfizer Malaysia; is now an employee with AiCuris AG.AC, no conflicts declared.FK, no conflicts declared.MP, no conflicts declaredOC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley.
